Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease
Go back to Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease| Johnson & Johnson (NYSE: JNJ) | Delayed: 228.39 -5.81 (2.48%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $234.20 | 52 Week High | $126.07 | |||
| Open | $231.78 | 52 Week Low | $94.28 | |||
| Day High | $232.75 | P/E | 47.48 | |||
| Day Low | $227.60 | EPS | $4.81 | |||
| Volume | 19,019,104 | |||||
